INVESTIGATION OF CO-TRIMOXAZOLE EFFICIENCY USING THE EXPERIMENTAL TUBERCULOSIS MODEL IN MICE CAUSED BY TUBERCULOUS MYCOBACTERIA WITH EXTENSIVE DRUG RESISTANCE
https://doi.org/10.21292/2075-1230-2017-95-2-51-58
Abstract
The efficiency of using co-trimoxazole for treatment of mice infected with tuberculous mycobacteria with extensive drug resistance and supposed sensitivity to co-trimoxazole have been investigated.
The study of 78 clinical cultures of tuberculous mycobacteria has demonstrated that drug resistance to first line drugs (cases with multiple drug resistance – MDR) can be accompanied by the expansion of polymorphism in the part of drug susceptibility to co-trimoxazole, thus this drug can be used as an additional drug in the treatment of M/XDR tuberculosis patients. Using co-trimoxazole as an additional drug to isoniazid in the model of generalized tuberculosis in mice infected with Beijing strain with XDR reduced the bacterial load of the lungs by 10 times.
Detail evaluation of drug susceptibility/resistance of tuberculous mycobacteria to the additional drug of co-trimoxazole and investigation of the interaction of this drug with other agents included into treatment regimens IV and V can form the basis for improvement of treatment regimens for M/XDR tuberculosis patients with specification of doses and frequency of drug in-takes for each specific case.
About the Authors
S. A. Popov
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of Microbiological Laboratory,
4, Dostoevsky St., Moscow, 127994
G. N. Mozhokina
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Doctor of Medical Sciences, Head of Department for Laboratory Testing in Phthisiology,
4, Dostoevsky St., Moscow, 127994
S. A. Kosenkov
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Post Graduate Student of Post-Graduate Training Programs,
4, Dostoevsky St., Moscow, 127994
N. A. Elistratova
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Candidate of Biological Sciences, Senior Researcher of Microbiological Laboratory,
4, Dostoevsky St., Moscow, 127994
T. P. Sabgayda
Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University;
Central Research Institute for Public Health Organization and Informatization
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor,
4, Dostoevsky St., Moscow, 127994
References
1. Edict no. 109 by On Tuberculosis Control Activities Improvement in the Russian Federation by Russian Ministry of Health as of 21.03.2003 Moscow, 2003, 169 p. (In Russ.)
2. Popov S.А., Puzanov V.А., Rusch-Gerdes S., Siddiqi S. H. Systema MGIT dlya kulturalnoy diagnostiki i opredeleniya lekarstvennoy chuvstvitelnosti mikobakteriy tuberkuleza. Standartnye operatsionnye protsedury. [MGIT for culture diagnostics and drug susceptibility testing of tuberculosis mycobacteria. Standard operation procedures]. Moscow, 2007, 24 p.
3. Rukovodstvo po primeneniyu nabora reagentov dlya spoligotipirovaniya mikobakteriy tuberkuleza chelovecheskogo i bychego tipov metodom gibridizatsii na biologicheskom mikrochipe. [Guidelines on using the set of reagents for spoligotyping of tuberculous mycobacteria of human and bovine species by hybridization technique on the biological microchip]. Registration Certificate no. FSR 2012/13826 as of 30.08.2012 of the RF Federal Health Care and Social Development Surveillance Service.
4. Ameen S.M., Rolain J.M., Poullain M.N. et al. Serum concentration of co-trimoxazole during a high-dosage regimen. J. Antimicrob. Chemother., 2014, vol. 69, pp. 757-760.
5. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.4. EUCAST. November 2014, 68 p.
6. Forgacs P., Wengenack N.L., Hall L. et al. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother., 2009, vol. 53, pp. 4789-4793.
7. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a public health approach. 7 August 2006/ WHO department of HIV/AIDS. Geneva, Sw., 68 p. http://www.who.int/hiv/pub/guidelines/ctx/en/
8. Huang T.S., Kunin C.M., Yan B.S. et al. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J. Antimicrob. Chemother., 2012, vol. 67, pp. 633-637.
9. Klemens S.P., Destefano M.S., Cynamon M.H. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother., 1993, vol. 37, no. 11. pp. 2344-2347.
10. Mokrousov I. Insights into the origin, emergence, and current spread of a successful russian clone of Mycobacterium tuberculosis. Clin. Microbiol Rev., 2013, vol. 26, no. 2, pp. 342-360.
11. Nunn A.J., Mwaba P., Chintu C. et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ, 2008, no. 337, pp. a257.
12. Rusch-Gerdes S., Pfyffer G. E., Chadwick C.M., Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol., 2006, Mar, pp. 688-692.
13. WHO Updated interim critical concentration for 1st and 2nd line DST (May 2012)/ http://www.stoptb.org/wg/gli/assets/documents/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf
14. Woods G.L., Brown-Elliot B.A., Conville P.S. et al. M24-A2 Susceptibility testing of Mycobacteria, Nocardiae and other aerobic Actinomycetes; Approved standard - second edition/ Clinical and laboratory standard institute. USA, NLCSI, 2011, 65 p.
15. Zachariah R., Massaquoi M. Co-trimoxazole prophylaxis for HIV-positive TB patients in developing countries. Trop. Doct., 2006, vol. 36, no. 2, pp. 79-82.
Review
For citations:
Popov S.A., Mozhokina G.N., Kosenkov S.A., Elistratova N.A., Sabgayda T.P. INVESTIGATION OF CO-TRIMOXAZOLE EFFICIENCY USING THE EXPERIMENTAL TUBERCULOSIS MODEL IN MICE CAUSED BY TUBERCULOUS MYCOBACTERIA WITH EXTENSIVE DRUG RESISTANCE. Tuberculosis and Lung Diseases. 2017;95(2):51-58. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-2-51-58
Views:
936
Email this article 